İbrahim Öner Doğan

İbrahim Öner Doğan

Auto-generated profile, based on publicly available information

İbrahim Öner Doğan

Koç University Hospital Faculty of Medicine, Department of Pathology, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Turkish Journal of Hematology
Verified
Journal Article
Open access
NBNeslihan Berker
Neslihan Berker
YÖYasemin Özlük
Yasemin Özlük
GYGulcin Yegen
Gulcin Yegen
İDİbrahim Öner Doğan
İbrahim Öner Doğan
Objective: Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous disease that is classified into germinal center B-cell (GCB) and non-GCB subtypes, which are prognostically different. The Hans algorithm is the most widely used tool based on CD10, BCL6, and MUM1 expression, but some cases with the non-GCB phenotype are still known to be misclassified. In this study, we investigate the extent to which GCET1, HGAL, and LMO2 protein expressions reflect GCB phenotype together with their roles in determining the GCB phenotype of DLBCL and their contributions to the performance of the Hans algorithm.Materials and Methods: Sixty-five cases of DLBCL-not otherwise specified, 40 cases of follicular lymphoma (FL), and 19 non-GC-derived lymphoma cases were included in this study. The DLBCL cases were grouped as CD10+ (Group A) or only MUM1+ (Group B), and the remaining cases constituted the intermediate group (Group C). GCET1, HGAL, and LMO2 expressions were evaluated.Results: In the FL group, GCET1, HGAL, and LMO2 were positive in 85%, 77.5%, and 100% of the cases, respectively. Among the non-GC derived lymphoma cases, all three markers were negative in cases of small lymphocytic lymphoma, plasmablastic lymphoma, peripheral T-cell lymphoma, and anaplastic large cell lymphoma. GCET1 and HGAL were negative in cases of marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL). Two of the 3 MZL and 2 of the 4 MCL cases were positive for LMO2. In the DLBCL group, the number of cases with GCET1, HGAL, and LMO2 positivity was 18 (90%), 17 (85%), and 20 (100%), respectively, in Group A and 0 (0%), 2 (13.3%), and 2 (13.3%), respectively, in Group B. Considering these rates, when the cases in the intermediate group were evaluated, it was concluded that 13 cases typed as non-GCB according to the Hans algorithm may have the GCB phenotype.Conclusion: GCET1, HGAL, and LMO2 are highly sensitive markers for determining the germinal center cell phenotype and can increase the accuracy of the subclassification of DLBCL cases, especially for cases that are negative for CD10.

30 May 2023 in Turkish Journal of Hematology
Verified
Journal Article
Open access
NYNese Yeldir
Nese Yeldir
TTTaner Tan
Taner Tan
OAOlga Meltem Akay
Olga Meltem Akay
İDİbrahim Öner Doğan
İbrahim Öner Doğan

14 November 2024 in Journal of Current Hematology & Oncology Research
Verified
Journal Article
Open access
PDF file
TTTaner Tan
Taner Tan
İDİbrahim Öner Doğan
İbrahim Öner Doğan
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag
With the introduction of many new treatments in multiple myeloma and the effective use of autologous stem cell transplantation, significant prolongation of overall survival has been achieved. Despite this ,there is still no cure for this disease. Relapses/refractory conditions seen after multiple treatments have brought the use of new agents to the agenda. Elranatamab is a humanized bispecific antibody used in relapsed or refractory multiple myeloma which targets B-cell maturation antigen on myeloma cells and CD3 on T cells . With this mechanism, elranatamab could activate T cells to induce cytotoxic T-cell response against myeloma cells. (1) Although we have an idea and experience about the short-term adverse effect profile and management, our ideas about the long-term adverse effect and safety profile are not yet clear due to the fact that it is a very new agent. We described an unexpected hematologic event during the use of elranatamab in the following case.

17 February 2025 in Turkish Journal of Hematology
Verified
Journal Article
Open access
TTTaner Tan
Taner Tan
MBMustafa Cem Bülbül
Mustafa Cem Bülbül
MKMerve Kaysin
Merve Kaysin
İDİbrahim Öner Doğan
İbrahim Öner Doğan
OAOlga Meltem Akay
Olga Meltem Akay
SBSinem Cıvrız Bozdağ
Sinem Cıvrız Bozdağ